Mode
Text Size
Log in / Sign up
N/A Completed N=52 Randomized Single-blind Treatment

Non-Inferiority Study of the FRESCA Airbox Positive Airway Pressure System

Source: ClinicalTrials.gov NCT03999944 ↗
Enrolled (actual)
52
Serious AEs
0.0%
Results posted
Jun 2021
Primary outcomePrimary: Apnea-Hypopnea Index (AHI) — 3.20; 4.86 events/hr

Summary

Prospective, open-label, randomized crossover assignment, multi-center non-inferiority study conducted in the United States

Outcome Measures

OutcomeResultp-value
PRIMARY
Apnea-Hypopnea Index (AHI)
3.20; 4.86
SECONDARY
Oxygen Desaturation Index (ODI)
3.12; 4.69

Eligibility Criteria

Inclusion Criteria

  • Male or female aged 22 - 75 years old.
  • BMI: ≤ 40 kg/m2.
  • Subjects diagnosed with OSA (either newly diagnosed (naive) OSA subjects or current CPAP subjects).
  • Must be able to be fitted properly with FRESCA mask.
  • Must be able to comply with all study requirements as outlined in the protocol.
  • Subject must complete a valid PSG titration night.

Exclusion Criteria

  • Subjects with non-OSA sleep disorders (including periodic limb movement (PLM) disorder and chronic insomnia).
  • Subjects with substantial central or mixed apneas (central and mixed apnea ≥ 5/hr.).
  • Subjects with prior surgical intervention for OSA.
  • Subjects with frequent or sustained episodes of O2 saturation ≤75%.
  • Subjects with obesity-related hypoventilation.
  • Subjects currently using a CPAP full face mask.
  • Subjects who are medically unstable.
  • Subjects with unstable or severe cardiovascular abnormalities (e.g., heart failure, valvular heart disease).
  • Subjects with atrial fibrillation or other arrhythmias that are not effectively controlled with medication.
  • Subjects with hypotension or uncontrolled HTN.
  • Subjects with chronic lung disease, including COPD.
  • Subjects with significant cardiopulmonary disease.
  • Subjects with ongoing severe nasal allergies or sinusitis or difficulty breathing through the nose; persistent blockage of one or both nostrils; or any nasal or facial abnormalities that would not allow adequate placement and use of the mask.
  • Subjects with surgery of the upper airway, nose, sinus or middle ear within the previous year.
  • Subjects currently working nights, rotating night shifts or with planned travel during the study period.
  • Subjects on a non-stable dose of medications or other agents that may affect sleep and/or PSG (e.g., sedatives or hypnotics).
  • Subjects who consume > 500 mg caffeine per day (e.g., > 8 cola-type beverages, > 5 cups of coffee).
  • Subjects who consume > 14 alcoholic drinks/week.
  • Subjects who are pregnant (confirmed verbally).
  • Subjects currently enrolled in any other research study.
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT03999944). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.

Back to search